Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05849922 · ClinicalTrials.gov registry record · Phase 2

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa, sponsored by Sanofi.

Completed
Registry status
Phase 2
Development phase
86
Enrollment target
20
Study locations

NCT05849922 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Sanofi. The registered enrollment target is 86 participants, below the 596-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05849922, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 2
Development phase
86 participants
Enrollment target
20
Study locations

Study Summary

This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG Placebo
  • DRUG SAR442970

Study Locations (20)

Other

  • Investigational Site Number : 0560001 - Leuven
  • Investigational Site Number : 1240007 - Québec
  • Investigational Site Number : 2030003 - Ostrava - Poruba
  • Investigational Site Number : 2030001 - Prague
  • Investigational Site Number : 2030002 - Praha 5 - Motol
  • Investigational Site Number : 2080001 - Roskilde

Ontario

  • Investigational Site Number : 1240001 - Barrie
  • Investigational Site Number : 1240002 - London
  • Investigational Site Number : 1240004 - Newmarket

Reg Metropolitana de Santiago

  • Investigational Site Number : 1520003 - Santiago
  • Investigational Site Number : 1520001 - Santiago
  • Investigational Site Number : 1520002 - Santiago

Florida

  • Renstar Medical Research Site Number : 8400011 - Ocala
  • ForCare Clinical Research Site Number : 8400006 - Tampa

Arizona

  • Medical Dermatology Specialists Site Number : 8400007 - Phoenix

Georgia

  • Advanced Medical Research PC Site Number : 8400002 - Sandy Springs

Rhode Island

  • Clinical Partners, LLC Site Number : 8400010 - Johnston

Texas

  • Center for Clinical Studies, LTD. LLP Site Number : 8400003 - Houston

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2023-06-06
Est. Completion 2025-01-09
Phase Phase 2

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05849922

The ClinicalTrials.gov registry entry for NCT05849922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 596-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (86% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05849922 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Ontario, Reg Metropolitana de Santiago.

Frequently Asked Questions

What is clinical trial NCT05849922 about?

NCT05849922 is a clinical study titled "A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa". This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.

What is the current status of trial NCT05849922?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2023-06-06. Estimated completion is 2025-01-09.

What conditions does trial NCT05849922 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT05849922?

The interventions under investigation include: Placebo (DRUG), SAR442970 (DRUG).

Who is sponsoring clinical trial NCT05849922?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05849922 being conducted?

This trial has 20 study locations across Arizona, Florida, Georgia, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.